Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.

In this retrospective cohort study, researchers found that exposure to 5-alpha reductase inhibitors and spironolactone in female alopecia patients was not linked to an increased risk of developing malignant or benign gynecologic tumors when compared to minoxidil use.

This study found a complex relationship between cumulative doses of 5-ARIs and all-cause mortality among BPH or AGA patients, with lower doses linked to higher suicide rates and higher doses reducing cardiovascular mortality risk.

According to this review, frontal fibrosing alopecia in men exhibits unique clinical features and is often misdiagnosed, underscoring the need for validated diagnostic criteria and treatment evaluation.

In clinical studies, inhibiting androgen receptor expression using CosmeRNA ARI SAMiRNA micelles effectively treated androgenetic alopecia by significantly increasing hair growth, as reported in this research.

This nested case-control study observed that patients with benign prostatic hyperplasia or androgenic alopecia who had a cumulative 5-ARI dose exceeding 5840 defined daily doses had a significantly reduced mortality risk, while lower doses were linked to higher mortality and suicide rates.

In this systematic review and meta-analysis, the authors found no statistically significant association between the use of 5α-reductase inhibitors and the risk of depression or suicide among over two million studied patients.

This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.

This study suggests that 5α-reductase inhibitors do not significantly affect male reproductive function but may require caution in men with oligospermia or ejaculatory issues.

This research highlights that while minoxidil and 5-alpha reductase inhibitors are commonly used for treating pattern hair loss, there is limited evidence supporting their relative effectiveness in women compared to men.

This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.

This review summarizes existing literature on oral finasteride's pharmacology, efficacy, and side effects for treating female pattern hair loss, and explores alternative options like topical finasteride and dutasteride; it reports no new results.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

This review analyzes existing literature on prognostic factors for renal cell carcinoma, highlighting the need for continuous updates of prognostic models to reflect advancement in molecular pathway knowledge and targeted therapies.

This historical review traces the discovery of 5-alpha reductase inhibitors, widely used in urology, from the study of guevedoces, Dominican children with a rare disorder leading to significant androgenization at puberty.

This study reviewed 18 postmenopausal women with frontal fibrosing alopecia, noting frontotemporal hairline recession and eyebrow loss, often treated with steroids, triamcinolone, and other medications.

5-ARI therapy may help prevent prostate cancer progression.

In this study, men using Propecia for alopecia showed normal erectile hemodynamics despite erectile dysfunction after stopping 5-alpha reductase inhibitors, while some BPH patients exhibited abnormal results potentially linked to vascular risk factors.

This study found that the epithelial changes in benign prostatic hyperplasia treated with finasteride resembled the pattern of healthy prostates.

This source reports that in men treated with 5α-reductase inhibitors for androgenetic alopecia, sexual adverse events such as decreased libido and erectile dysfunction occurred at rates from 1.9% to 12% in clinical trials, with effects often being mild and reversible upon stopping treatment.

This study reviewed recent scientific evidence on the neuroendocrine and metabolic impacts of chronic use of 5-alpha reductase inhibitors, detailing its association with sexual dysfunction, mood disorders, insulin resistance, and other metabolic disorders, suggesting persistent biopsycho-social risks beyond transient side effects in users.

In this study, dermatologists from the Spanish Hair and Nail Disorders Group viewed post-finasteride syndrome as rare and primarily of psychiatric origin, with limited scientific evidence supporting its existence.

This study found that the 4Kscore model, when adjusted for kallikrein marker changes due to finasteride use, improved the prediction of high-grade prostate cancer compared to adjusted total PSA alone in men taking 5-α-reductase inhibitors.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.

In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.

This Swedish cohort study found no association between the use of anti-androgenic 5α-reductase inhibitors and improved 5-year all-cause or disease-specific mortality in oesophago-gastric cancer patients, challenging the hypothesis that these drugs enhance survival outcomes.

This case report observed that hypogonadism and cold sensation resolved in a patient after discontinuing 5-alpha-reductase inhibitors, suggesting these medications may contribute to such symptoms.